

PATENT Attorney Docket No. 01197.0277

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:		
Ayako Hashimoto et al.		Group Art Unit: 1625
Application No.: 10/587,045		Examiner: Celia C. Chang
Filed: July 24, 2000	3	
For: Pharmaceuti Promoting A	cal Composition for ngiogenesis	Confirmation No.: 8787

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

REPLY

In response to the Restriction Requirement of July 1, 2009, Applicants elect Group II and the subject matter of claims 3-4 for further prosecution in this application.

In response to the requirement for a single disclosed disorder wherein angiogeneiss is promoted, Applicants elect myocardial infarction. In response to the requirement for a specific piperdine compound, Applicants elect the compound of claim 2.

A Preliminary Amendment is being filed simultaneously with this Reply to place the claims in proper format and permit the Examiner to consider all of claims 1-4. All of claims 1-4 are readable on the elected species.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GABRETT & DUNNER, L.L.P.

Dated: July 30, 2009

Arthur S. Garrett Reg. No. 20,338

(202) 408-4091

1892596_1.DOC